Alector, Inc. (ALEC) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 38 days, typically, give or take 9 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Nov 5, 2026after close 36 8-K
Q2 FY2026Thu, Aug 6, 2026after close 37 8-K
Q1 FY2026Thu, May 7, 2026after close 37 8-K
Q4 FY2025Wed, Feb 25, 2026after close 56 8-K
Q3 FY2025Thu, Nov 6, 2025after close 37 8-K
Q2 FY2025Thu, Aug 7, 2025after close 38 8-K
Q1 FY2025Thu, May 8, 2025after close 38 8-K
Q4 FY2024Wed, Feb 26, 2025after close 57 8-K

What they guided beta

Q3 FY2026 "EX-99.1 Exhibit 99.1 Alector Reports Third Quarter 2026 Financial Results and Provides Business Update Advancing a pipeline built entirely on the Alector Brain Carrier (ABC) blood-brain barrier platform, spanning antibody, enzyme, and siRNA programs, with AL137, Alector's lead ABC-enabled anti-amyloid beta (Aβ) antibody program for Alzheimer's disease (AD), targeting first-in-human dosing in Australia no later than April 2027." exhibit
Q3 FY2026 "Continued progress across AL164 (ABC-enabled Tau siRNA for AD and other tauopathies) and AL062 (ABC-enabled alpha-synuclein siRNA for Parkinson's disease (PD) and Lewy body dementia (LBD)), each targeting first-in-human studies in Q2 2028." exhibit
Q3 FY2026 "Completed underwritten offering for gross proceeds of approximately $75 million, priced at a premium to market, with participation from top-tier new and existing investors. $138.7 million in cash, cash equivalents and investments as of September 30, 2026; Together with proceeds from the Genentech license agreement and approximately $75.0 million in gross proceeds from the underwritten offering, expected to fund operations into the second half of 2029. --- SOUTH SAN FRANCISCO, Calif., Nov. 5, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developin" exhibit
Q3 FY2026 "With AL137 targeting first-in-human dosing no later than April 2027, and AL164 and AL062 targeting first-in-human studies in Q2 2028, we are advancing toward multiple clinical readouts as we work to bring new options to patients with neurodegenerative diseases.”" exhibit
Q3 FY2026 "Alector submitted a Human Research Ethics Committee (HREC) registration in Australia in October 2026 and is targeting first-in-human SC dosing in healthy volunteers in Australia no later than April 2027." exhibit
Q2 FY2026 "The company is targeting an IND submission in Q1 2027 and first-in-human dosing in Australia no later than April 2027." exhibit
Q2 FY2026 "Management anticipates that this will be sufficient to fund Alector’s operations at least through 2027." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ALEC
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ALEC

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

ALEC earnings date badge

HTML

<a href="https://veritasdata.dev/company/ALEC/"><img src="https://veritasdata.dev/embed/ALEC.svg" alt="ALEC earnings date" width="240" height="56"></a>

Markdown

[![ALEC earnings date](https://veritasdata.dev/embed/ALEC.svg)](https://veritasdata.dev/company/ALEC/)

Script

<script async src="https://veritasdata.dev/embed/ALEC.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ALEC"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.